Referência Bibliográfica Suplementar.
1.
Amy Butler,
Greenfield. A Perfect Red: Empire, Espionage, and the Quest for the Color of
Desire (em Inglês). [S.l.]: HarperCollins, 2005. 352 p. 1 vol.
vol. 1. ISBN 0-06-052275-5
2.
ATS Committe
on proficiency standards for clinical pulmonary function laboratories. ATS
statement: guidelines for the six-minute walk test. Am J Crit Car Med. 2002;
166 (1): 111-7.
3.
A randomized
trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol
Study (CIBIS). CIBIS Investigators and Committees.
Circulation. 1994; 90 (4): 1765 -73.
4.
Acmite Market
Intelligence: Market Report: World Pigment Market.
5.
Ceresana
Research: Market Study: Pigments.
6.
Connor, Steve.
(9 de Setembro 2006). "Body art made its mark 300,000 years ago,
scientists claim" (em Inglês). The Independent. Visitado em
04/07/2012.
7.
Cassinge,
Ruth. Dyes:: From Sea Snails to Synthetics (em Inglês). 1ªd ed. [S.l.]:
Twenty-First Century Books, 2003. 80 p. 1 vol. vol. 1. ISBN 0-7613-2112-8
8.
Chidsey CA,
Morselli P, Bianchetti G, Marganti A, Leonetti G, Zanchetti A. Studies of the
absorption and removal of propranolol in hypertensive patients during therapy. Circulation.
1975; 52 (2): 313-8.
9.
Bilchick KC,
Fetics B, Djoukeng R, Fisher SG, Fletcher RD, Singh SN, et al. Prognostic
values of heart rate variability in chronic congestive heart failure (Veterans
Affairs' Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure).
Am J Cardiol. 2002; 90 (1): 24-8.
10.
Becquemont L
(2009). "Pharmacogenomics of adverse drug reactions: practical
applications and perspectives". Pharmacogenomics 10 (6): 961–9.
doi:10.2217/pgs.09.37. PMID 19530963.
11.
COSTA, M. A. et al. Terapêutica pediátrica em
ambulatório: notas, conselhos, esquemas posológicos. 2ª edição. Lisboa: 2010.
274 p.
12.
COSTAIN, Lyndel. Super Nutrientes / Título
original: Super Nutrients; Tradução Lenora Matteucci. São Paulo: Publifolha,
2005. 128 p.
13.
CELMO CELENO PORTO, Doenças do coração:
prevenção e tratamento. 2ª edição - Rio de Janeiro: Guanabara Koogan, 2005.
1118 p.
14.
COSTA, E. D. A. Nutrição e frutoterapia:
tratamento alternativo através das frutas. Rio de Janeiro: Vozes, 2011. 220 p.
15.
CHAVES, A.J. L. Viva melhor: com a medicina do
lar. 7º Edição. Lisboa: 2006. 416 p.
16.
CHAVES, A.J. L. Viva melhor: com as plantas
medicinais. 7º Edição. Lisboa: 2008. 512 p.
17.
CALADO, A.A; et al. Urologia geral para o
estudante de medicina. Recife: Editora Universidade de Pernambuco, 2010. 177 p.
18.
COZZOLINO, S. M. F. Biodisponibilidade de
nutrientes. 4ª edição. São Paulo: Manole, 2012. 1334 p.
19.
CURTIS, Susan. et al. O livro das receitas das
ervas medicinais. São Paulo: Publifolha, 2011. 352p.
20. Cluett E R, Nikodem VC, McCandlish RE, Burns EE. Immersion
in water in pregnancy, labour and birth. Cochrane Database of Systematic
Reviews 2002, Issue 2. Art. No.: CD000111. DOI: 10.1002/14651858.CD000111.pub2.
Available from World Wide Web: < http://www.cochrane.org/reviews/en/ab000111.html
>
21.
Crang C.
Learning to cope with the fatigue caused by cancer. Nurs
Times 1999;95(16):53-5.
22.
Conlee RK.
Muscle glycogen and exercise endurance: a twenty-year perspective. Exerc
Sport Sci Rev. 1987; 15:1-28.
23.
Coyle EF,
Coggan AR, Hemmert MK, Ivy JL. Muscle glycogen utilization during prolonged
strenuous exercise when fed carbohydrate. J Appl Physiol. 1986;
61(1):165-72.
24.
Costill DL,
Bowers R, Branam G, Sparks K. Muscle glycogen utilization during prolonged
exercise on successive days. J Appl Physiol. 1971; 31(6): 834-8.
25.
Carlos Barros e Wilson Paulino. Ciência - O
Corpo Humano. Editora Ática. Página 171 ISBN 978-85 08 12256-1
26.
Coggan AR.
Plasma glucose metabolism during exercise in humans. Sports
Med. 1991; 11(2):102-24.
27.
Christ-Roberts
CY, Pratipanawatr T, Pratipanawatr W, Berria R, Belfort R, Mandarino LJ.
Increased insulin receptor signaling and glycogen synthase activity contribute
to the synergistic effect of exercise on insulin action. J Appl
Physiol. 2003; 95(6):2519-29.
28.
Coggan AR,
Raguso CA, Williams BD, Sidossis LS, Gastaldelli A. Glucose kinetics during
high-intensity exercise in endurance-trained and untrained humans. J
Appl Physiol. 1995; 78(3): 1203-7.
29.
Conlee RK,
Lawler RM, Ross PE. Effects of glucose or fructose feeding on glycogen
repletion in muscle and liver after exercise or fasting. Ann
Nutr Metab. 1987; 31(2):126-32.
30.
Chin ER, Allen
DG. Effects of reduced muscle glycogen concentration on force, Ca+2 release and
contractile protein function in intact mouse skeletal muscle. J
Physiol. 1997; 498(Pt 1):17-29.
31.
Costill DL,
Gollnick PD, Jansson ED, Saltin B, Stein EM. Glycogen depletion pattern in
human muscle fibres during distance running. Acta Physiol
Scand. 1973; 89(3):374-83.
32.
Cochran AJ,
Bailly C, Eberhard P, Remotti F. Melanocytic tumors: a guide to diagnoses. Philadelphia:
Lippincott-Raven; 1997.
33.
COLLEGY OF
PHARMACY. The University of Rhode Island. IMODR: Basic Pharmacokinetic and
Pharmacodynamic Models. Online:
34.
http://www.uri.edu/pharmacy/faculty/rosenbaum/basicmodels.
Último acesso em: Março, 2014.
35.
Chadda KK,
Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial
infarction in patients with congestive heart failure. Circulation.
1986; 73 (3): 503-10.
36.
De Mey C, Breithaupt-Grogler K, Schloos J,
Palm D, Belz GG. Reproducibility and consistency of the responses to supine
bicycle ergometry: evaluation in conjunction with β-1
adrenoreceptor occupancies. Br J
Clin Pharm. 1994; 38 (5): 480-3
37.
Effect of metoprolol CR/XL in chronic
heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive
Heart Failure (MERIT-HF). Lancet.
1999; 353 (9169): 2001-7.
38.
Flather MD, Shibata MC, Coats AJ, Van
Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine
the effect of nebivolol on mortality and cardiovascular hospital admission in
elderly patients with heart failure (SENIORS). Eur Heart J. 2005; 26 (3): 215-25.
39.
Flannery G, Gehrig-Mills R, Billah B, Krum
H. Analysis of randomized controlled trials on the effect of magnitude of heart
rate reduction on clinical outcomes in patients with systolic chronic heart
failure receiving beta-blockers. Am J Cardiol. 2008; 101 (6): 865-9
40.
Goodman
& Gilman. As bases farmacológicas da terapêutica. [tradução da 10. ed.
original, Carla de Melo Vorsatz. et al] Rio de Janeiro: McGraw-Hill, 2005
41.
Guidance
for Industry Pharmacogenomic Data Submissions (PDF) Administração de Alimentos
e Medicamentos (March 2005). Visitado em 10 de junho de 2006.
42.
Galinier M, Pathak A, Fourcade J,
Androdias C, Curnier D, Varnous S, et al. Depressed low frequency power of
heart rate variability as an independent predictor of sudden death in chronic
heart failure. Eur Heart J.
2000; 21 (6): 475-82.
43.
Gilbert EM, Abraham WT, Olsen S, Hattler
B, White M Mealy P, Larrabee P, et al. Comparative hemodynamic, left
ventricular functional, and antiadrenergic effects of chronic treatment with
metoprolol versus carvedilol in the failing heart. Circulation. 1996; 94 (11):
2817-25.
44.
http://www.aulete.com.br/patela
45.
http://www.sbcancer.org.br/home2/site/index.php?option=com_content&view=article&id=117:cancer-osseo&catid=29&Itemid=123
46.
http://www.institutodocancer.com.br/php/index.php?link=5&sub=19
47.
http://www.aulete.com.br/c%C3%BAbito
48.
http://www.scielo.br/scielo.php?pid=S0365-05962010000400021&script=sci_arttext
49.
http://www.ncbi.nlm.nih.gov/pubmed/7009438
50.
http://www2.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/pele_melanoma
51.
http://ligacontracancro.pt/gca/index.php?id=201
52.
http://www.skincancer.org/skin-cancer-information/melanoma/types-of-melanoma
53.
http://www.skincancer.org/skin-cancer-information/melanoma
54.
http://www.puc-campinas.edu.br/centros/ccv/revcienciasmedicas/artigos/v15n5a10.pdf)
55.
http://www.merckmanuals.com/professional/clinical_pharmacology/pharmacodynamics/overview_of_pharmacodynamics.html
56.
http://www.uri.edu/pharmacy/faculty/rosenbaum/basicmodels.
Último acesso em: Março, 2014.
57.
http://www.merckmanuals.com/professional/clinical_pharmacology/pharmacodynamics/overview_of_pharmacodynamics.html
58.
http://www.merckmanuals.com/professional/clinical_pharmacology/pharmacodynamics/overview_of_pharmacodynamics.html
59.
http://www.merckmanuals.com/professional/clinical_pharmacology/pharmacodynamics/overview_of_pharmacodynamics.html
60.
http://en.wikipedia.org/wiki/Paraneoplastic_syndrome
61.
http://www.ninds.nih.gov/disorders/paraneoplastic/paraneoplastic.htm
62.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931619/
63.
http://www.skincancer.org/skin-cancer-information/basal-cell-carcinoma
64.
http://www.manuaismsd.pt/?id=72
65.
HARUO
PASSEROTTI, Gustavo (Maio de 2003). Barotrauma em Otorrinolaringologia (PDF)
(em português) Fundação Otorrinolaringologia. Visitado em 12 de dezembro de
2013.
66.
JG Pires, R Maggio, C Manes, P Palumbo, On
the importance of pharmacokinetics and pharmacodynamics in engineering sciences
as an inter- and multidisciplinary field: an introductory analysis. SIMPEP 2014.
67.
Lees P, Cunningham FM, Elliott J (2004). "Principles
of pharmacodynamics and their applications in veterinary pharmacology". J. Vet. Pharmacol. Ther. 27 (6):
397–414. doi:10.1111/j.1365-2885.2004.00620.x. PMID 15601436.
68.
Mulliken JB, Fishman SJ, Burrows PE. Vascular anomalies. Curr Probl Surg
2000; 37(8): 518-84.
69.
Mulliken JB, Gloawacki, J. Hemangiomas and
vascular malformations in infants and children: a classification based on
endothelial characteristics. Plast
Reconstr Surg 1982; 69(3): 412-20.
70.
Metry DW, Hebert AA. Benign cutaneous
vascular tumors of infancy: when to worry, what to do. Arch Dermatol 2000; 136: 905-14.
71.
Marshall, A.D.; Grosveld, G.C.. (2012).
"Alveolar rhabdomyosarcoma – The molecular drivers of PAX3/7-FOXO1-induced
tumorigenesis". Skeletal
Muscle 2: 1-14.
72.
MCPHEE, Stephen J.; Papadakis, Maxine A.;
Rabow, Michael W... CURRENT:
Medicina (Lange) (em português). 51ª ed. Porto Alegre, Rio Grande do Sul: Grupo
A Educação, 2013. p. 190. ISBN 8580551870 Página visitada em 18 de dezembro de
2013.
73.
MOORE,K.L; DALLEY,F.A, AGUR.A.M.R.. (Maio/Junho de 2010). "Anatomia
orientada para clinica" (em português). Brazilian
Journal of Otorhinolaryngology 76 (3). São Paulo: Guanabara Koogan.
DOI:10.1590/S1808-86942010000300012. ISSN 1808-8694. Visitado em 12 de novembro de 2013.
74.
Malfatto
G, Facchini M, Branzi G, Riva B, Sala L, Perego GB. Long-term
treatment with the beta-blocker carvedilol restores autonomic tone and
responsiveness in patients with moderate heart failure. J Cardiovasc Pharmacol. 2003; 42 (1):
125-31.
75.
Mortara A, La Rovere MT, Pinna GD, Maestri
R, CapomollaS, Cobelli F. Nonselective beta adrenergic blocking agent
carvedilol, improves arterial baroflex gain and heart rate variability in
patients with stable chronic heart failure. J Am Coll Cardiol. 2000; 36: 1612 -8.
76.
Michel, Pastoreau. In: Princeton
University Press. Blue: the History of a Color (em Inglês). 1ªd ed.
[S.l.]: Twenty-First Century Books, 2001. 216 p. 1 vol.
vol. 1. ISBN
0-691-09050-5
77.
Mckee PA, Castelli WP, Mcnamara PM, Kannel
WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971; 285: 1441-6.
78.
Maia
ER, Villacorta H, Subietta GC, Munhoz C, Romeu-Filho LJM, Mesquita ET. Use of
propranolol in heart failure patients: safety, tolerability, and effects on
left ventricular function. Rev
Port Cardiol. 2001; 20 (4): 383-99.
79.
Manual
da gravidez semana a semana. Porto: Porto Editora, 2011. 288p.
80.
Simon Garfield. Mauve: How One Man
Invented a Color That Changed the World. [S.l.]: Faber and Faber, 2000. ISBN 0-393-02005-3
81.
Packer M, Bristow MR, Cohn JN, Collucci W,
Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure. U S Carvedilol Heart Failure
Study Group. N Engl J Med. 1996; 334 (21): 1349-55.
82.
Packer M, Coats AJS, Fowler MB, katus HA,
Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic
heart failure. N Engl J Med.
2001; 344 (22): 1651-8.
83.
Peris K, Ferrari A, Argenziano G, Soyer
HP, Chimenti S. Dermoscopic classification of Spitz/Reed nevi. Clin Dermatol. 2002; 20(3):259-62
84.
Rossotti. Colour: Why the World Isn't
Grey. Princeton, NJ: [s.n.], 1983. ISBN 0-691-02386-7
85.
Rowen D. Frandson, W. Lee Wilke, Anna Dee
Fails. Anatomy and Physiology of Farm Animals. Philadelphia, Pennsylvania, USA: Lea & Febiger, 1974, 429p.
86.
ROSENBAUM, S. E Basic pharmacokinetics and
pharmacodynamics: an integrated textbook and computer simulations, John Wiley
& Sons, 2011.
87.
ROSENBAUM, S. E Basic pharmacokinetics and
pharmacodynamics: an integrated textbook and computer simulations, John Wiley
& Sons, 2011.
88.
Squassina
A, Manchia M, Manolopoulos VG, Artac M, Lappa-Manakou C, Karkabouna S,
Mitropoulos K, Del Zompo M, Patrinos GP (2010). "Realities
and expectations of pharmacogenomics and personalized medicine: impact of
translating genetic knowledge into clinical practice". Pharmacogenomics 11 (8): 1149–67.
doi:10.2217/pgs.10.97. PMID 20712531.
89.
SHONKWILER, R. W.; HEROD, J. Mathematical
biology: an introduction with Maple and Matlab. Undergraduate texts in mathematics. Second Edition: Spring: 2009.
90.
Shearer J, Graham TE. Novel aspects of
skeletal muscle glycogen and its regulation during rest and exercise. Exerc Sports Sci Rev. 2004;
32(3):120-6.
91.
Spencer MK, Katz A. Role of glycogen in
control of glycolysis and IMP formation in human muscle during exercise. Am J Physiol. (Endocrinol Metab) 1991;
260(6 Pt 1): E859-64.
92.
Stevenson E, Williams C, Biscoe H. The
metabolic responses to high carbohydrate meals with different glycemic indices
consumed during recovery from prolonged strenuous exercise. Int J Sport Nutr Exerc Metab. 2005;
15(3):291-307.
93.
SIMON, M. I. S. S., SEGABINAZZI, E. A. L.,
CORBELLINI, N. M., et al. Manual
de Dietas Hospitalares. São Paulo: Editora Atheneu, 2014. 82 p.
94.
SERGIO
SEGANTINI. Insonia - como prevenir e tratar. Lisboa: Editorial Presença, 2009.
127 p.
95.
SOGIMIG,
Manual de ginecologia e obstetrícia da Associação de ginecologistas e obstetras
de Minas Gerais. 5ª edição - Belo Horizonte: COOPMED 2012. 1344 p.
96.
SCHMIDT,
I. Léxico de plantas medicinais. 1ªedição. Lisboa: Dinalivro, 2007. 288 p.
97.
SANTOS,
A. D. D. Guia de saúde e alimentos funcionais: saúde através dos alimentos. Rio
de Janeiro: Ciência moderna, 2010. 284 p.
98.
SPETHMANN,
C. N. Medicina alternativa de A a Z. 7ª edição. Uberlândia, Minas Gerais:
Natureza, 2004. 391 p.
99.
SOUZA,
J.B.D. Engravidar: sim é possível. 1ª Edição. São Paulo: Alaúde Editorial,
2010. 126 p.
100.
SOUZA,
M. D. L. Cuidando da Saúde. 1ª Edição. São Paulo: Paulinas, 2008. 294 p
101.
SOUZA,
B. B. A D. et al. Nutrição e disfagia: Guia para profissionais. Curitiba:
Nutroclínica, 2203. 60p.
102.
STEFFENHAGEN,
M. K. Manual da Coluna, 22ª edição. Curitiba: Cócegas, 2011. 156 p.
103.
SILVA,
A.R. Tudo sobre aromaterapia. 2ª edição. São Paulo: Roka, 1998. 576 p.
104.
SOARES,
Carlos A. Verduras e legumes que curam. Rio de Janeiro: Vozes, 2013. 204p.
105.
SHONKWILER, R. W.; HEROD, J. Mathematical
biology: an introduction with Maple and Matlab. Undergraduate texts in mathematics. Second Edition: Spring: 2009.
106.
Talwar KK, Bhargava B, Upasani PT, Verma
S, Kamlakar T, Chopra P. Hemodynamic predictors of early intolerance and
long-term effects of propranolol in dilated cardiomyopathy. J Card Fail. 1996; 2 (4): 273-7.
107.
The Cardiac Insufficiency Bisoprolol Study
II (CIBIS II): a randomised trial. Lancet. 1999; 353 (9146): 9-13.
108.
Tavares
LR, Victer H, Linhares JM, Barros CM, Oliveira MV, Pacheco LC, et al. Epidemiology
of decompensated heart failure in the city of Niterói - EPICA - Niterói
Project. Arq Bras Cardiol.
2001; 82 (2): 125-8.
109.
Talwar KK, Bhargava B, Upasani PT, Verma
S, Kamlakar T, Chopra P. Hemodynamic predictors of early intolerance and
long-term effects of propranolol in dilated cardiomyopathy. J Card Fail. 1996; 2 (4): 273-7.
110.
Teopompo,
citado por Ateneu, de acordo com Charles Barton Gulick em Athenaeus, The
Deipnosophists. Cambridge: Harvard University Press, 1941
111.
van Campen LCMC, Visser F, Visser CA. Ejection
fraction improvement by β-blocker
treatment in patients with heart failure: an analysis of studies published in
the literature. J Cardiovasc
Pharmacol. 1998; 32 (1): S31-5.
112.
YOUNG, Barbara; Stevens, Alan; S. Lowe,
James. Wheater
histologia funcional: texto e atlas em cores (em português). [S.l.]: Elsevier
Brasil, 2007. p. 417. ISBN 8535218599 Página visitada em 12 de dezembro de
2013.
113.
Wang L (2010). "Pharmacogenomics: a
systems approach". Wiley Interdiscip Rev Syst Biol Med 2 (1): 3–22.
doi:10.1002/wsbm.42. PMID
20836007.
114.
Wouters, Jan; Rosário-Chirinos, Noemi. (9
de Setembro 2006). "Dye Analysis of Pre-Columbian Peruvian Textiles with
High-Performance Liquid Chromatography and Diode-Array Detection" (em
Inglês). Journal of the American Institute for Conservation 31 (2): 237-255.
Washington: The American Institute for Conservation of Historic & Artistic
Works. DOI:10.2307/3179495.
Visitado em 04/07/2012.
115.
Wang
L., (2010; Becquemont L., (2009; janeiro de 2016; Squassina A, Manchia M, Manolopoulos VG,
Artac M, Lappa-Manakou C, Karkabouna S, Mitropoulos K, Del Zompo M, Patrinos
GP., (2010)
116.
Waagstein F, Caidahl K, Wallentin I, Berg
C, Hjalmaroson A. Long-term beta-blockade in dilated cardiomyopathy: effects of
short- and long-term metoprolol treatment followed by withdrawal and
readministration of metoprolol. Circulation.
1989; 80 (3): 551-63.
117.
Waagstein F, Hjalmarson A C, Wasir HS. Apex
cardiogram and sistolic time intervals in acute myocardial infarction and
effects of practolol. Br
Heart J. 1974; 36 (11): 1109-21.
118.
Waagstein F, Hjalmarson A, Varnauskas E,
Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive
cardiomyopathy. Br Heart J. 1975;
37 (10): 1022-36.
119.
Waagstein F, Bristow MR, Swedberg K,
Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in
idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC)
Trial Study Group. Lancet. 1993; 342 (8885): 1441-6.
120.
KÄLLÉN, A. Computational pharmacokinetics.
Chapman and Hall/CRC Biostatistics Series, 2008.
121.
KATZUNG, B. G.; MASTERS, S. B.; TREVOR, A.
J. Basic and clinical pharmacology. 12th edition. McGraw Hill. 2012.
Nenhum comentário:
Postar um comentário